Ingredient Safety Dossiers: Building a Defensible Package for Novel Actives 

Companies developing Cosmetics with new or unusual active ingredients face a higher regulatory bar in India than those using well-established formulations. Understanding what “new” means under the Cosmetics Rules, 2020, and what needs to go into a safety dossier, can save months of delay at the approval stage. 

Step One: Find Out If Your Ingredient Is Actually “New” 

The 2020 Rules define a “New Cosmetic” as one that contains a novel ingredient — meaning an ingredient that has not been used anywhere in the world in Cosmetics or is not recognized for cosmetic use in any national or international literature. This definition is found in Rule 3(r) of the Rules. 

This is a narrower category than it might sound. An ingredient does not need to be brand new to science to fall outside this definition — it only needs to be recognized somewhere, in some country’s Cosmetic literature, for cosmetic use. Many “innovative” ingredients used in Indian Cosmetics are, in fact, already recognized elsewhere and therefore do not trigger the New-Cosmetic pathway. 

The practical first step, before building any dossier, is a literature and regulatory search: has this ingredient been used or recognized in Cosmetics anywhere else? The answer determines which pathway your product follows. 

If It Is a New Cosmetic: What CDSCO Requires 

If your ingredient does meet the “New Cosmetic” definition, the product cannot be manufactured or imported without prior permission from the Central Licensing Authority. The process works roughly as follows: 

1. Application filing. The company applies using Form COS-12, submitted through the SUGAM online portal. 

2. Safety and efficacy data. The application must be accompanied by data demonstrating both the safety and the effectiveness of the product — not just safety alone. 

3. Testing standard. Safety evaluation must be carried out using the methods specified in IS 4011:2018, the Bureau of Indian Standards’ methods of test for safety evaluation of Cosmetics, as amended. 

4. Approval. If the Central Licensing Authority is satisfied, permission is granted in Form COS-3, after which the company can proceed to apply for a manufacturing license or import registration. 

Skipping the literature search and assuming a well-known active elsewhere is automatically “recognized” in this framework is a common and costly mistake — the recognition needs to be traceable to actual national or international cosmetic literature, not just marketing use. 

What Should Go into the Dossier 

A well-built safety dossier for a novel active generally contains: 

• Ingredient identity and characterization. Chemical name, source, method of manufacture or extraction, and purity specifications. 

• Literature review. A documented search showing whether, and where, the ingredient has prior cosmetic use or recognition — this supports the “New Cosmetic” determination itself. 

• Safety testing data, per IS 4011:2018. This includes the specific test methods required under the standard, conducted by an appropriately qualified laboratory. 

• Concentration and exposure rationale. Evidence that the concentration used in the finished product is safe for the intended use — skin contact, frequency of application, and target consumer group all matter here. 

• Efficacy data. Since new Cosmetics require both safety and effectiveness data, the dossier should also demonstrate that the ingredient does what it is claimed to do, using methods appropriate to that specific claim. 

• No animal testing declaration. India maintains a statutory ban on animal testing for Cosmetics and their ingredients. Applicants must submit a signed and stamped self-declaration confirming that the product and its ingredients have not been tested on animals, both at the registration stage and afterward. 

A Note on Reusing Global Dossiers 

Many companies already hold a safety dossier prepared for the EU, the US, or another market, and want to reuse it for India. This is a reasonable starting point, but it is not usually a direct substitute. The testing methods behind a global dossier may not align with IS 4011:2018, and the “new cosmetic” determination itself depends on Indian-specific recognition criteria, not just global novelty. Treat an existing global dossier as a source of raw data to be re-mapped against Indian requirements, rather than a document that can be submitted as-is. 

Why Getting This Right EarlyMatters 

A dossier built without a clear literature search at the start often runs into one of two problems later: either the company under-prepares, assuming the ingredient is not “new” when it in fact is, and the application is rejected or delayed; or the company over-prepares, assembling a full new-cosmetic dossier for an ingredient that was already recognized and did not need one, losing time and money. 

Getting the classification right at the outset — new cosmetic or not — should be treated as the first milestone in any product development timeline that involves a distinctive or proprietary active ingredient. 

Summary

The safety dossier is not paperwork created to satisfy a regulator after the fact — it is the technical foundation that both the approval and the eventual marketing claims rest on. 

Building it properly, in the right format, against the right standard, from the start of development is far more efficient than retrofitting one under approval pressure. 

The final article in this set looks at a related and often confusing area: where cosmetic claims cross the line and risk having a product reclassified as a drug. 

Conclusion

• Determine early whether the proposed product qualifies as a “new cosmetic” under Rule 3(r). 

• Conduct a documented literature and regulatory assessment before preparing the dossier. 

• Submit Form COS-12 with appropriate safety, effectiveness, quality, composition, and supporting data. 

• Ensure safety evaluation follows IS 4011:2018, as amended from time to time. 

• Include relevant specifications, labelling, undesirable-effect information, and claimed-benefit evidence. 

• Existing global dossiers should be reviewed and mapped against Indian regulatory requirements. 

Proper classification and early dossier planning can reduce regulatory queries, delays, and unnecessary testing costs.